Neuroborreliosis: When Lyme Crosses the Blood-Brain Barrier

The following is an illustrative composite of a presentation we see often, not a single identifiable patient.

A 42-year-old teacher arrives at our hospital. Three different specialists have told her she has depression, early-onset dementia, and fibromyalgia. She cannot remember her students’ names. She has word-finding difficulties that terrify her. She wakes at 3 a.m. with a sensation she describes as electrical buzzing in her skull. Her psychiatric medications have not helped.

Her Lyme serology was “equivocal” two years ago, and no one followed up.

Her picture fits neuroborreliosis, not depression or dementia. St. George Hospital has treated more than 12,000 Lyme patients over three decades, and this presentation is common there.

At a Glance

How Borrelia Reaches the Brain

Borrelia burgdorferi sensu lato is among the most neurotropic bacteria known to medicine. Within days to weeks of initial infection, spirochetes can cross the blood-brain barrier through multiple mechanisms [1]:

Direct penetration. Borrelia exploits the paracellular junctions of the blood-brain barrier endothelium. The spirochete’s corkscrew motility and narrow diameter allow it to penetrate gaps between endothelial cells, particularly when the barrier is compromised by the inflammatory response to infection itself.

Trojan horse mechanism. Borrelia has been demonstrated to adhere to and be carried across the blood-brain barrier (BBB) within monocytes and other immune cells, hitchhiking into the central nervous system (CNS) inside the very cells sent to fight it [2].

Choroid plexus entry. The choroid plexus, which produces cerebrospinal fluid, has a less restrictive barrier than cerebral capillaries. Borrelia can enter the CSF via this route and then disseminate throughout the CNS.

Once inside the central nervous system, Borrelia triggers a cascade of neuroinflammation. Activated microglia and astrocytes release inflammatory cytokines (TNF-alpha, IL-6, IL-8), creating a hostile neurological environment that persists even after the bacterial load is reduced. Neurological symptoms in neuroborreliosis are therefore driven by both the infection and the inflammatory response to it, so killing the bacteria is necessary but not sufficient.

The Neuropsychiatric Presentation

This is what the research actually says about neuroborreliosis symptom patterns, alongside what I observe clinically:

Cognitive Impairment

The most common and most distressing feature. Patients describe:

• Word-finding difficulties (anomic aphasia)
• Short-term memory loss
• Processing speed reduction: “thinking through fog”
• Difficulty with multitasking and executive function
• Disorientation in familiar environments

These symptoms are measurable on neuropsychological testing. In our patient population, approximately 70% of neuroborreliosis patients show objective cognitive deficits on formal assessment, even when their presenting complaint was primarily physical [3].

Psychiatric Manifestations

Neuroborreliosis can present as virtually any psychiatric condition:

• Depression: often atypical, with prominent fatigue and cognitive features rather than primarily mood disturbance
• Anxiety and panic attacks: frequently with a somatic quality patients describe as “chemical” rather than psychological
• Irritability and rage: disproportionate to circumstances, often alarming to the patient themselves
• Depersonalization and derealization: the sense of being disconnected from one’s body or surroundings
• Psychosis: rare but documented, including paranoid ideation and hallucinations [4]

When a patient develops new-onset psychiatric symptoms after a tick bite, after unexplained febrile illness, or alongside other Lyme-compatible symptoms, neuropsychiatric Lyme must be on the differential. It frequently is not. Too many of our patients were prescribed psychiatric medications for years before anyone investigated Borrelia.

Cranial Neuropathies

Facial nerve palsy (Bell’s palsy) is the classic neuroborreliosis presentation and is reasonably well recognized. In European endemic areas, Lyme is the leading cause of bilateral facial palsy.

But other cranial nerves are also affected. I see:

• Optic neuritis (cranial nerve II)
• Oculomotor disturbances (cranial nerves III, IV, VI): double vision, difficulty tracking
• Vestibular dysfunction (cranial nerve VIII): vertigo, disequilibrium
• Trigeminal neuralgia (cranial nerve V): facial pain, often misdiagnosed as dental pathology

Radiculopathy and Myelopathy

Bannwarth syndrome (meningoradiculitis with severe radicular pain, often nocturnal, accompanied by an increased white cell count in the cerebrospinal fluid, called CSF pleocytosis) is a well-established neuroborreliosis presentation, particularly common in European Lyme (B. garinii). Patients describe burning, boring pain that wakes them from sleep and does not respond to conventional analgesics.

In our neuropathy protocol, we add fat-soluble thiamine, specifically benfotiamine at 300 mg twice daily, given its capacity to activate transketolase, suppress advanced glycation end-product formation, and restore the mitochondrial enzymatic function that Borrelia-driven inflammation disrupts in radicular and peripheral neurons.

In severe cases, Borrelia myelitis can cause spinal cord inflammation with motor weakness, sensory loss, and even bladder dysfunction, a presentation frequently mistaken for multiple sclerosis.

Diagnostic Challenges

The CSF Problem

The standard diagnostic approach for neuroborreliosis is lumbar puncture with CSF analysis. The European guidelines look for:

• Lymphocytic pleocytosis (elevated white cells in CSF)
• Elevated CSF protein
• Intrathecal antibody production (CSF-to-serum antibody index)

These criteria perform well in acute, early neuroborreliosis. In chronic or late-stage disease, which is what we predominantly see, CSF may be normal or show only subtle abnormalities [5]. The intrathecal antibody index can remain positive for years after successful treatment, making it unreliable as a marker of active disease. And in some patients, CSF antibodies are never detectable despite clear neurological involvement.

In our experience, a normal lumbar puncture does not exclude neuroborreliosis. It makes the diagnosis less straightforward, but if the clinical picture is compelling and other diagnoses have been excluded, a normal CSF should not be the reason a patient is denied treatment.

Serology Limitations

The two-tier serological testing approach (ELISA followed by Western blot) was designed for epidemiological surveillance, not for individual clinical diagnosis. Its sensitivity in early disease is poor (30-40% in the first weeks), and in disseminated disease, false negatives occur at rates that should concern every clinician [6].

At our clinic, we have treated patients with unambiguous neuroborreliosis (PCR-positive CSF, response to antimicrobial therapy) whose initial two-tier serology was negative. The test is useful when positive. A negative result does not exclude the diagnosis.

Advanced Diagnostics

At our hospital, we use a multimodal diagnostic approach:

• ELISPOT/LTT (lymphocyte transformation test): Measures T-cell reactivity to Borrelia antigens. More sensitive than antibody-based tests for detecting active infection, particularly in late-stage disease.
• CD57+ NK cell count: Chronically low counts correlate with persistent Borrelia infection in our clinical observations and published literature.
• SPECT or PET neuroimaging: Can demonstrate cerebral hypoperfusion patterns characteristic of neuroinflammation. Not specific to Lyme but supports the diagnosis in the appropriate clinical context.
• Full co-infection panel: Babesia, Bartonella, Ehrlichia, Anaplasma, Mycoplasma. Co-infections are common in chronic Lyme patients and can complicate the neurological picture.

Treatment: Why Antibiotics Are Necessary but Not Sufficient

Standard neuroborreliosis treatment in European guidelines is intravenous ceftriaxone for 14-21 days. This is reasonable for acute neuroborreliosis and often effective. I do not dispute this.

But for chronic neuroborreliosis, in a patient who has had CNS symptoms for months or years, has failed standard antibiotic courses, and has persistent neuroinflammation, IV ceftriaxone monotherapy is frequently inadequate. The reasons are biological:

1. Borrelia persister forms. Borrelia can convert to round body and biofilm forms that are metabolically dormant and resistant to cell-wall-active antibiotics like ceftriaxone [7].
2. CNS antibiotic penetration. While ceftriaxone achieves reasonable CSF levels, penetration into brain parenchyma, perivascular spaces, and intracellular compartments is limited.
3. Ongoing neuroinflammation. Even when the bacteria are killed, the inflammatory cascade in the CNS can persist autonomously, driven by activated microglia and residual bacterial debris.

This is where our multimodal approach becomes essential.

Whole-Body Hyperthermia for Neuroborreliosis

Whole-body hyperthermia is, in my clinical assessment, the single most important treatment tool for neuroborreliosis. Here is why.

Borrelia burgdorferi is thermolabile. In laboratory cultures at the University of Graz, Prof. Reisinger’s group found that Borrelia growth was inhibited at 39-40 degrees Celsius and that a bactericidal effect appeared at 41 degrees C for two of three strains and at 42 degrees C for all strains [8]. These are in-vitro data; killing of Borrelia by heat has not been measured in patients.

Heat reaches the brain. Core body temperature elevation to 41.6-41.8 degrees C raises tissue temperature throughout the body, including the brain, so heat does not face the penetration limits that antibiotics do. Whether this translates into a clinical effect on neuroborreliosis has not been tested in controlled trials.

Our protocol uses a Heckel whole-body hyperthermia device. The patient is sedated and their core temperature is raised to 41.6-41.8 degrees C for a defined period, typically two sessions separated by several days. It is medically controlled hyperthermia performed under clinical supervision with continuous vital sign monitoring, quite unlike a sauna or hot bath.

There are no published outcome figures for this protocol in neuroborreliosis, and no controlled trials. A Herxheimer-type reaction can occur during antimicrobial or hyperthermia treatment. It is not proof that a treatment is working, and its absence does not mean failure.

I want to be transparent about the evidence level: our clinical data is extensive but institutional. We do not yet have multicenter randomized controlled trials of hyperthermia for neuroborreliosis. The mechanistic rationale is strong (thermolability is established), and the clinical observations across thousands of patients are consistent. This deserves rigorous trial validation, and I believe it will withstand that scrutiny.

Transcranial Pulse Stimulation for Neuroregeneration

Killing Borrelia in the CNS is the first step. Repairing the damage is the second. This is where Transcranial Pulse Stimulation (TPS) has become central to our neuroborreliosis protocol.

TPS delivers focused, low-energy shockwaves to targeted brain regions. The mechanism of action involves:

• Mechanotransduction: Shockwaves stimulate neuronal growth factor expression (BDNF, VEGF, NGF)
• Neuroplasticity activation: Promotes synaptogenesis and dendritic remodeling
• Anti-inflammatory effects: Modulates microglial activation from pro-inflammatory (M1) to reparative (M2) phenotype
• Improved cerebral perfusion: Restores blood flow to hypoperfused regions

For neuroborreliosis specifically, TPS addresses the neuroinflammatory and neurodegenerative damage that persists after the infection is treated. In my clinical experience, patients who receive TPS after hyperthermia show faster and more complete cognitive recovery than those treated with antimicrobials and hyperthermia alone.

A typical protocol involves six to ten TPS sessions, each targeting brain regions identified as hypoperfused or dysfunctional on neuroimaging. The treatment is non-invasive, performed in an outpatient setting, and well tolerated. I discuss TPS in greater detail in the context of all neurological conditions.

The Complete Neuroborreliosis Protocol

Drawing on St. George Hospital’s experience treating over 12,000 Lyme patients, our approach to neuroborreliosis follows this sequence:

Phase 1: Diagnostics (Days 1-3)

• Serological and cellular immune testing for Borrelia and co-infections
• Neuropsychological testing (baseline)
• SPECT or functional neuroimaging
• Inflammatory markers, oxidative stress parameters
• Complete metabolic and nutritional assessment

Phase 2: Preparation (Days 3-5)

• Begin IV antimicrobial therapy (combination approach targeting active and persister forms)
• Nutritional optimization and detoxification support
• Management of any co-infections identified
• Apheresis in selected patients with high inflammatory burden

Phase 3: Hyperthermia (Days 5-10)

• Whole-body hyperthermia session 1: 41.6-41.8 degrees C
• Recovery and Herxheimer management
• Continued antimicrobials and supportive care
• Whole-body hyperthermia session 2: three to five days after session 1

Phase 4: Neuroregeneration (Days 10-21)

• TPS sessions (typically 6-10, every one to two days)
• Continuation of antimicrobial therapy
• IV laser therapy for immune modulation and vascular support
• Repeat neuropsychological testing

Phase 5: Long-Term Support

• Oral antimicrobial continuation as clinically indicated
• Immune support protocol (thymosin alpha-1, nutritional optimization)
• Follow-up TPS sessions at three and six months if needed
• Serial monitoring of Lyme-specific immune markers

What I Observe in Practice

St. George Hospital has treated neuroborreliosis for three decades, work my father pioneered and I now continue. Certain patterns are consistent:

Cognitive recovery is often dramatic. Patients who could not read a book or follow a conversation before treatment frequently report significant cognitive improvement within weeks of hyperthermia, and in our patients the change shows up on formal neuropsychological testing.

Psychiatric symptoms improve with infection treatment, not psychiatric medication. The patients who were on antidepressants for years without benefit often improve substantially once the underlying neuroborreliosis is treated. Psychiatry has its place; the point is an accurate diagnosis.

Co-infections complicate everything. Bartonella has its own neurotropic properties and can cause neuropsychiatric symptoms independently. Babesia causes cerebral hypoperfusion. Addressing Lyme without addressing co-infections yields incomplete results.

Earlier treatment produces better outcomes. The patient treated within the first year of neurological symptoms responds faster and more completely than the patient who has had untreated neuroborreliosis for five years. Late-stage patients should not be discouraged, since improvement is still the norm, but the difference shows the cost of diagnostic delay.

The Herxheimer reaction is informative. A strong Herxheimer response after hyperthermia (transient worsening of neurological symptoms followed by improvement) supports both the diagnosis and the treatment response, though it does not prove either. Patients who experience the most intense Herxheimer reactions often show the most dramatic improvement afterward.

Safety and Considerations

Whole-body hyperthermia for neuroborreliosis is a medical procedure with real risks that requires experienced clinical management:

• Cardiovascular stress: Core temperature elevation places demand on the cardiovascular system. Patients undergo cardiac screening before treatment. Active cardiac disease is a contraindication.
• Seizure risk: Theoretical concern given CNS involvement. We use appropriate sedation protocols and continuous EEG monitoring.
• Herxheimer management: Massive spirochete die-off can temporarily worsen symptoms. Supportive care, hydration, and in some cases IV steroids are used to manage severe reactions.
• Not suitable for all patients. Pregnancy, severe cardiac disease, recent stroke, and certain other conditions preclude hyperthermia. Patient selection is critical.

TPS is well tolerated with minimal side effects. Transient headache and mild fatigue are occasionally reported.

The Bottom Line

Neuroborreliosis is underdiagnosed, undertreated, and frequently mistaken for psychiatric or neurodegenerative disease. The blood-brain barrier that protects the brain from most pathogens also protects Borrelia from most antibiotics, creating a sanctuary that conventional treatment struggles to reach. Whole-body hyperthermia exploits the thermolability of Borrelia, reaches every compartment including the CNS, and in our institutional clinical experience produces meaningful neurological improvement in the majority of patients. Combined with TPS for neuroregeneration and targeted antimicrobial therapy, neuroborreliosis is treatable. The first step is recognizing it.